Gaviria-Mendoza Andres, Machado-Duque Manuel E, Machado-Alba Jorge E
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma, S. A., Pereira, Colombia; Grupo de Investigación en Biomedicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
Biomedica. 2019 Dec 1;39(4):759-768. doi: 10.7705/biomedica.4801.
Lipid-lowering drugs, especially statins, have shown great relevance in preventing and treating cardiovascular diseases.
To determine the prescription patterns of lipid-lowering drugs and the variables associated with their use in a Colombian population.
This is a cross-sectional descriptive study. From a drug dispensing database of approximately 4.5 million Colombian health system affiliates, patients of all ages and both sexes treated with lipid-lowering agents (statins, fibrates, ezetimibe) were identified between January and March, 2017. Demographic, pharmacological and co-medication variables were included.
In total, 103,624 patients were identified as being treated with lipid-lowering agents. The average age was 67.5 years, and 49.8% were 65 years or older. Women comprised 58.0% of the patients. Statins were the most used (n=96,910; 93.5%), and atorvastatin (n=80,812; 78.0%) and lovastatin (n=12,621; 12.2%) were the most frequent. The mean atorvastatin dose was 30.3 mg/day, and 49.9% of its users received presentations of 40 mg or more. A total of 9,258 (8.9%) patients received fibrates, and only 780 (0.8%) were taking ezetimibe. Of this population, 94.9% were treated with lipid-lowering monotherapy, and 97.3% (n=100,813) had co-medication for their comorbidities, with the most frequent being antihypertensive (89.1%), antiplatelet (57.8%), antidiabetic (31.5%) and antiulcerative agents (34.2%).
Atorvastatin is currently the most frequently used lipid-lowering drug in this group of Colombian patients, especially in monotherapy and at doses close to the defined daily dose. Only half received high-intensity doses. New studies are required to verify the efficacy of these therapies.
降脂药物,尤其是他汀类药物,在预防和治疗心血管疾病方面已显示出重大关联。
确定哥伦比亚人群中降脂药物的处方模式及其使用相关变量。
这是一项横断面描述性研究。从约450万哥伦比亚卫生系统附属机构的药品配发数据库中,识别出2017年1月至3月期间接受降脂药物(他汀类、贝特类、依折麦布)治疗的所有年龄和性别的患者。纳入了人口统计学、药理学和合并用药变量。
总共识别出103,624名接受降脂药物治疗的患者。平均年龄为67.5岁,49.8%的患者年龄在65岁及以上。女性占患者的58.0%。他汀类药物使用最为广泛(n = 96,910;93.5%),阿托伐他汀(n = 80,812;78.0%)和洛伐他汀(n = 12,621;12.2%)最为常用。阿托伐他汀的平均剂量为30.3毫克/天,其使用者中有49.9%接受40毫克或更高剂量的剂型。共有9,258名(8.9%)患者接受贝特类药物治疗,仅780名(0.8%)服用依折麦布。在该人群中,94.9%接受降脂单一疗法治疗,97.3%(n = 100,813)因合并症接受合并用药,最常用的药物为抗高血压药(89.1%)、抗血小板药(57.8%)、抗糖尿病药(31.5%)和抗溃疡药(34.2%)。
阿托伐他汀目前是这组哥伦比亚患者中最常用的降脂药物,尤其是在单一疗法中,且剂量接近规定日剂量。只有一半患者接受高强度剂量。需要开展新的研究以验证这些疗法的疗效。